Sirtex Medical (ASX: SRX), a biotech company that specialises in liver cancer treatments, jumped 7% higher to around $11 on Thursday after an upgrade from Macquarie.
"Macquarie rates SIRTEX MEDICAL as Outperform, with a price target of $14.30. Macquarie is very confident about the growth prospects for this company, not just in terms of market conditions but also clinical outcomes, new avenues for growth and the strategic direction."
Sirtex shares have jumped 113% over the past year on the back of strong dose sales of its SIR-Spheres microspheres targeted radioactive liver cancer treatment. Although trading at a premium valuation, the future continues to look bright for Sirtex.
If you are looking for the next small cap stock to rocket higher, The Motley Fool's FREE report titled Two Small Cap Superstars could be just for you. Click here now to access this free brand-new research report, including names, codes, and all the details of the two "superstars."
More reading
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Motley Fool General Manager Bruce Jackson doesn't own shares in any companies mentioned in this article.
